• Blau Farmacêutica investor presentation outlined a capacity expansion plan targeting 48% near-term growth, rising to 3x with a Pernambuco complex.
• Pipeline focus on monoclonal antibodies, supported by more than 80 R&D projects, positioned as a key growth driver.
• International strategy highlighted operations in nine countries across the Americas, with expectations that new capacity supports wider regional reach.
• Investment program cited more than BRL 1.5 billion deployed since the IPO, backed by low leverage and strong operating cash generation.
• Company reported 2025 net revenue of BRL 1.75 billion, with hospital products representing 85% of sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blau Farmaceutica SA published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.